Table 3.
Univariate and multivariate analyses for relapse free survival
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95 % CI | P | HR | 95 % CI | P | |
| Age (≤median) | 0.685 | 0.364–1.287 | 0.240 | - | ||
| Menopausal status (Premenopausal) | 0.846 | 0.449–1.594 | 0.605 | - | ||
| pCR | 0.342 | 0.082–1.420 | 0.140 | - | ||
| AJCC response (CR plus PR) | 0.309 | 0.172–0.556 | 0.000 | 0.374 | 0.192–0.728 | 0.004 |
| Surgery (BCS) | 0.428 | 0.228–0.803 | 0.008 | 0.475 | 0.252–0.894 | 0.021 |
| Pathologic Stage (yp0,I) | 0.235 | 0.092–0.600 | 0.002 | 0.267 | 0.094–0.756 | 0.013 |
| Hormone receptor positive | 0.447 | 0.236–0.846 | 0.013 | 0.402 | 0.198–0.818 | 0.012 |
| HER2 positive | 1.059 | 0.761–1.474 | 0.734 | - | ||
| TNBC | 1.038 | 0.056–2.131 | 0.919 | - | ||
| Subtype (Luminal A) | 0.379 | 0.145–0.985 | 0.047 | 0.314 | 0.103–0.962 | 0.043 |
pCR pathologic complete response, CR complete response, PR partial response, BCS breast conserving surgery, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer, HR hazard ratio, 95 % CI 95 % confidence interval, P p-value